Invention Grant
- Patent Title: PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
-
Application No.: US16947583Application Date: 2020-08-07
-
Publication No.: US11780923B2Publication Date: 2023-10-10
- Inventor: Xiangdong Qu , Qiyue Hu , Shaoyu Xu , Dongbing Cui , Houcong Jin , Weikang Tao , Lianshan Zhang , Guoqing Cao , Piaoyang Sun
- Applicant: Suzhou Suncadia Biopharmaceuticals Co., Ltd. , Jiangsu Hengrui Medicine Co., Ltd. , Shanghai Hengrui Pharmaceutical Co., Ltd.
- Applicant Address: CN Jiangsu
- Assignee: Suzhou Suncadia Biopharmaceuticals Co., Ltd.,Jiangsu Hengrui Medicine Co., Ltd.,Shanghai Hengrui Pharmaceutical Co., Ltd.
- Current Assignee: Suzhou Suncadia Biopharmaceuticals Co., Ltd.,Jiangsu Hengrui Medicine Co., Ltd.,Shanghai Hengrui Pharmaceutical Co., Ltd.
- Current Assignee Address: CN Jiangsu; CN Lianyungang; CN Shanghai
- Agency: Ice Miller LLP
- Priority: CN 1510788907.3 2015.11.17
- The original application number of the division: US15775598
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/395 ; A61P35/00 ; A61K39/00
Abstract:
The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
Information query
